Download PDF
CC BY-NC-ND 4.0 · South Asian J Cancer 2021; 10(02): 53-57
DOI: 10.1055/s-0041-1734336
Original Article: Bone and Soft Tissue Cancers

Trabectedin in Advanced Sarcomas—Experience at a Tertiary Care Center and Review of Literature

Saurav Verma
1   Department of Medical Oncology, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India
,
Kaushal Kalra
1   Department of Medical Oncology, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India
,
Sameer Rastogi
1   Department of Medical Oncology, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India
,
Ekta Dhamija
2   Department of Radiology, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India
,
Avinash Upadhyay
1   Department of Medical Oncology, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India
,
Abhenil Mittal
1   Department of Medical Oncology, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India
,
Aditi Aggarwal
3   Department of Radiotherapy, National Cancer Institute, Haryana, Jhajjar, India
,
Shamim Ahmed Shamim
4   Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India
› Author Affiliations
› Further Information
   Permissions and Reprints

Abstract

Background There is sparse literature on trabectedin in advanced soft-tissue sarcomas from developing world. It would be interesting to know about use and outcomes of trabectedin in Indian patients.

Method In a retrospective study, consecutive patients treated with trabectedin from 2016 to 2019 were analyzed. Patients with L-sarcomas were treated at a dose of 1.5 mg/m2, while those with translocation-related sarcomas were treated at a dose of 1.2 mg/m2 as a 24-hour infusion through peripherally inserted central catheter line. From July 2019, infusions were administered through an ambulatory elastomeric pump, while before that patients were admitted for 24 hours. We used SPSS version 23.0 for statistical calculation.

Result A total of 20 patients received trabectedin with a total of 116 infusions. The median age was 46 years (range: 22–73 years). The male (n = 11, 55%) and female patients were almost equal (n = 9, 45%). Thirteen patients (65%) had Eastern Cooperative Oncology Group Performance Status 1. Majority of the patients had leiomyosarcoma (n = 8, 40%); remaining comprised of liposarcoma (3, 15%), translocation-related sarcomas excluding myxoid liposarcoma (n = 8, 40%) and others (n = 1,5%). Most common site was extremity (n = 11, 55%) followed by retroperitoneal (n = 3, 15%), visceral (n = 3, 15%), and others (n = 3,15%). Median number of previous lines received was 2 (range: 0–4). Median number of trabectedin cycles received was 4 (range: 1–17). Best response assessed was stable disease (n = 10, 50%), progressive disease (n = 6, 30%), partial response (n = 1, 5%), and not assessed in 3 patients. After a median follow-up of 19 months, median progression-free survival was 4 months.

Conclusion In this heavily treated population (composed of L-sarcomas and translocation-related sarcomas) with many patients with poor performance status, the outcome with trabectedin is in synchrony with literature. However, the need of 24-hour admission might deter quality of life. Elastomeric pump seems to be a reasonable alternative to admission and can be a breakthrough in administering trabectedin, especially in developing countries.

Keywords

advanced sarcoma - elastomeric pump - L-sarcomas - leiomyosarcoma - trabectedin


Publication History

Article published online:
23 September 2021

© 2021. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Private Ltd
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • References

  • 1 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019; 69 (01) 7-34
    CrossrefPubMedGoogle Scholar
  • 2 van der Graaf WTA, Blay J-Y, Chawla SP. et al EORTC Soft Tissue and Bone Sarcoma Group, PALETTE study group. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012; 379 (9829) 1879-1886
    CrossrefPubMedGoogle Scholar
  • 3 Demetri GD, Schöffski P, Grignani G. et al. Activity of eribulin in patients with advanced liposarcoma demonstrated in a subgroup analysis from a randomized phase III study of eribulin versus dacarbazine. J Clin Oncol 2017; 35 (30) 3433-3439
    CrossrefPubMedGoogle Scholar
  • 4 Zewail-Foote M, Hurley LH. Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove. J Med Chem 1999; 42 (14) 2493-2497
    CrossrefPubMedGoogle Scholar
  • 5 Allavena P, Signorelli M, Chieppa M. et al. Anti-inflammatory properties of the novel antitumor agent Yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production. Cancer Res 2005; 65 (07) 2964-2971
    CrossrefPubMedGoogle Scholar
  • 6 Guirouilh-Barbat J, Redon C, Pommier Y. Transcription-coupled DNA double-strand breaks are mediated via the nucleotide excision repair and the Mre11-Rad50-Nbs1 complex. Mol Biol Cell 2008; 19 (09) 3969-3981
    CrossrefPubMedGoogle Scholar
  • 7 D’Incalci M, Badri N, Galmarini CM, Allavena P. Trabectedin, a drug acting on both cancer cells and the tumour microenvironment. Br J Cancer 2014; 111 (04) 646-650
    CrossrefPubMedGoogle Scholar
  • 8 Demetri GD, Chawla SP, von Mehren M. et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol 2009; 27 (25) 4188-4196
    CrossrefPubMedGoogle Scholar
  • 9 Monk BJ, Blessing JA, Street DG, Muller CY, Burke JJ, Hensley ML. A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: a gynecologic oncology group study. Gynecol Oncol 2012; 124 (01) 48-52
    CrossrefPubMedGoogle Scholar
  • 10 Yovine A, Riofrio M, Blay JY. et al. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol 2004; 22 (05) 890-899
    CrossrefPubMedGoogle Scholar
  • 11 Le Cesne A, Blay JY, Judson I. et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol 2005; 23 (03) 576-584
    CrossrefPubMedGoogle Scholar
  • 12 Demetri GD, von Mehren M, Jones RL. et al. Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial. J Clin Oncol 2016; 34 (08) 786-793
    CrossrefPubMedGoogle Scholar
  • 13 Rastogi S, Bakhshi S. Trabectedin in soft tissue sarcoma: have we hit the bull’s-eye. ? J Clin Oncol 2016; 34 (29) 3582-3583
    CrossrefPubMedGoogle Scholar
  • 14 Blay J-Y, Leahy MG, Nguyen BB. et al. Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas. Eur J Cancer 2014; 50 (06) 1137-1147
    CrossrefPubMedGoogle Scholar
  • 15 Kawai A, Araki N, Sugiura H. et al. Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 study. Lancet Oncol 2015; 16 (04) 406-416
    CrossrefPubMedGoogle Scholar
  • 16 Morioka H, Takahashi S, Araki N. et al. Results of sub-analysis of a phase 2 study on trabectedin treatment for extraskeletal myxoid chondrosarcoma and mesenchymal chondrosarcoma. BMC Cancer 2016; 16 (01) 479
    CrossrefPubMedGoogle Scholar
  • 17 Schöffski P, Cerbone L, Wolter P. et al. Administration of 24-h intravenous infusions of trabectedin in ambulatory patients with mesenchymal tumors via disposable elastomeric pumps: an effective and patient-friendly palliative treatment option. Onkologie 2012; 35 (1-2) 14-17
    CrossrefPubMedGoogle Scholar
  • 18 Twelves C, Hoekman K, Bowman A. et al. Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours. Eur J Cancer 2003; 39 (13) 1842-1851
    CrossrefPubMedGoogle Scholar
  • 19 Konstantinos E, Christos A, Chrysanthi K, Vassiliki T, Eleni T. Complete response after long-term 2nd line treatment with trabectedin in a hemodialyzed patient with metastatic high-grade ovarian sarcoma, case report and short review. Arch Clin Med Case Rep 2019; 3 (06) 591-599
    CrossrefGoogle Scholar
  • 20 Le Cesne A, Kapso Kapnang R, Foulon S, Bonastre J. 1604PDHealth-related quality of life in patients with advanced soft tissue sarcoma (ASTS): results from the TSAR randomized phase III trial of the French Sarcoma Group. Ann Oncol, 2018;29:(suppl_8) Available from: https://academic.oup.com/annonc/article/29/suppl_8/mdy299.003/5142270 Accessed July 19, 2021
    Google Scholar
  • 21 Gronchi A, Bui BN, Bonvalot S. et al. Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma. Ann Oncol 2012; 23 (03) 771-776
    CrossrefPubMedGoogle Scholar
  • 22 Gronchi A, Hindi N, Cruz J. et al. Trabectedin and RAdiotherapy in Soft Tissue Sarcoma (TRASTS): Results of a Phase I Study in Myxoid Liposarcoma from Spanish (GEIS), Italian (ISG), French (FSG) Sarcoma Groups. EClinicalMedicine 2019; 9: 35-43
    CrossrefPubMedGoogle Scholar
  • 23 Gronchi A, Le Cesne A, Bui NB. et al. A phase II clinical trial of neoadjuvant trabectedin in patients with nonmetastatic advanced myxoid/round cell liposarcoma (MRCL. J Clin Oncol 2009; 27 (15) suppl) 10525-10525
    CrossrefGoogle Scholar
  • 24 Pierantoni F, Maruzzo M, Brunello A. et al. Trabectedin drug holiday and rechallenge in soft tissue sarcomas: report of 4 cases and literature review. Front Oncol 2019; 9: 553 https://www.frontiersin.org/articles/10.3389/fonc.2019.00553/full cited2019Nov18 [Internet]
    CrossrefPubMedGoogle Scholar
  • 25 Kotecki N, Le Cesne A, Tresch-Bruneel E. et al. Impact of trabectedin interruption and subsequent rechallenge on progression in patients with advanced soft tissue sarcoma: long-term follow-up of the T-DIS trial. Am J Clin Oncol 2018; 41 (11) 1094-1100
    CrossrefPubMedGoogle Scholar
  • 26 Rastogi S, Kalra K, Manasa P, Rajawat M, Mehta V. Long lasting response of trabectedin in patient with gastric leiomyosarcoma with liver metastasis: an update to previous report. Future Sci OA 2019; 6 (01) FSO432
    CrossrefPubMedGoogle Scholar